Catalysts · JAZZ · CIK 1232524 · page 2 of 2

JAZZ catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on JAZZ PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
August 5, 2025—JAZZEarnings—CompletedSEC 8-K Exhibit 99.1
Aug 2025Month disclosedModeyso (dordaviprone)JAZZFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jun 2025Month disclosedTecentriq® (atezolizumab)JAZZLabel expansion—ApprovedSEC Form 10-Q
May 6, 2025—JAZZEarnings—CompletedSEC 8-K Exhibit 99.1
February 25, 2025Ziihera® (zanidatamab)JAZZFDA approvalwith previously treated, unresectable or metastatic HER2-positiveApprovedSEC 8-K Exhibit 99.1
February 25, 2025—JAZZEarnings—CompletedSEC 8-K Exhibit 99.1
1H 2025Half-year disclosedTecentriq® (atezolizumab)JAZZNDA/BLA submission—ScheduledSEC 8-K Exhibit 99.1
1H 2025Half-year disclosedZepzelca (lurbinectedin)JAZZNDA/BLA submission—ScheduledSEC 8-K Exhibit 99.1
2025Year disclosedJZP441JAZZTrial start—ScheduledSEC Form 10-K
1H 2025Half-year disclosedGEA-01JAZZNDA/BLA submission—ScheduledSEC 8-K Exhibit 99.1
November 20, 2024Ziihera® (zanidatamab)JAZZFDA approvalwith previously treated, unresectable or metastatic HER2-positiveApprovedSEC Form 8-K
Oct 2024Month disclosedZepzelca (lurbinectedin)JAZZTopline readout—Met primary endpointSEC Form 10-Q
Oct 2024Month disclosedTecentriq® (atezolizumab)JAZZTopline readout—Met primary endpointSEC Form 10-Q
Oct 2024Month disclosed—JAZZTopline readout—Met primary endpointSEC Form 10-Q
Nov 2022Month disclosedsuvecaltamide (JZP385)JAZZTrial startParkinson's disease tremorCompletedSEC Form 10-K
August 12, 2021Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate)JAZZLabel expansion—ApprovedopenFDA Drugs@FDA
July 21, 2020Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate)JAZZFDA approval—ApprovedopenFDA Drugs@FDA
June 15, 2020Zepzelca (lurbinectedin)JAZZFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from JAZZ’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.